Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 1
2014 1
2015 2
2016 2
2017 3
2018 2
2019 3
2020 3
2021 5
2022 6
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N, Aboubakar Nana F, Derijcke S, Kian W, Patel S, Gantz-Sorotsky H, Zer A, Moskovitz M, Metro G, Rottenberg Y, Calles A, Hochmair M, Cuppens K, Decoster L, Reck M, Limon D, Rodriguez E, Astaras C, Bettini A, Häfliger S, Addeo A. Bar J, et al. Among authors: moskovitz m. J Thorac Oncol. 2023 Feb;18(2):169-180. doi: 10.1016/j.jtho.2022.10.004. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307041 Free article.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Besse B, et al. Among authors: moskovitz mt. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. Nat Med. 2024. PMID: 38351187 Free PMC article. Clinical Trial.
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Moskovitz M, Dudnik E, Shamai S, Rotenberg Y, Popovich-Hadari N, Wollner M, Zer A, Gottfried M, Mishaeli M, Rosenberg SK, Onn A, Merimsky O, Urban D, Peled N, Maimon N, Bar J. Moskovitz M, et al. Oncologist. 2022 Feb 3;27(1):e76-e84. doi: 10.1093/oncolo/oyab005. Oncologist. 2022. PMID: 35305096 Free PMC article.
Pegfilgrastim overdose: case report and review of the literature.
Kaidar-Person O, Moskovitz M, Charas T, Alsharbati W, Haim N. Kaidar-Person O, et al. Among authors: moskovitz m. Med Oncol. 2011 Dec;28 Suppl 1:S697-8. doi: 10.1007/s12032-010-9751-5. Epub 2010 Nov 24. Med Oncol. 2011. PMID: 21107754 Review.
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.
Bar J, Leibowitz R, Reinmuth N, Ammendola A, Jacob E, Moskovitz M, Levy-Barda A, Lotem M, Katsenelson R, Agbarya A, Abu-Amna M, Gottfried M, Harkovsky T, Wolf I, Tepper E, Loewenthal G, Yellin B, Brody Y, Dahan N, Yanko M, Lahav C, Harel M, Raveh Shoval S, Elon Y, Sela I, Dicker AP, Shaked Y. Bar J, et al. Among authors: moskovitz m. Front Immunol. 2024 Feb 29;15:1364473. doi: 10.3389/fimmu.2024.1364473. eCollection 2024. Front Immunol. 2024. PMID: 38487531 Free PMC article.
28 results